Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOMET vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
~10-20% bound to plasma proteins (primarily albumin).
~16% bound to plasma proteins (primarily albumin).
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
None
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOMET vs ADDERALL 5, answered by our medical review team.
ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOMET and ADDERALL 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOMET and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.